Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure is under clinical development by Translational Biosciences and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure’s likelihood of approval (LoA) and phase transition for Rheumatoid Arthritis took place on 12 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure overview

Stem cell therapy (human umbilical cord tissue-derived mesenchymal stem cells) is under development for the treatment of rheumatoid arthritis. It is administered through intra-articular, intravenous, intrathecal and intratracheal route. It was also under development for the treatment of bronchopulmonary dysplasia, cerebral palsy, osteoarthritis, multiple sclerosis, spinal cord injury, heart failure and autism.

Quick View Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure LOA Data

Report Segments
  • Innovator
Drug Name
  • Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure
Administration Pathway
  • Intraarticular
  • Intrathecal
  • Intratracheal
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Immunology
  • Musculoskeletal Disorders
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.